AI-generated content for informational purposes only. Not financial advice. Always do your own research.

About

Thermo Fisher Scientific Inc. (TMO) is the world's largest life sciences tools and diagnostics company, serving pharmaceutical, biotech, academic, government, and healthcare customers with a comprehensive portfolio of instruments, reagents, consumables, and services. The company's scale, recurring revenue base, and consistent M&A strategy have driven double-digit earnings growth over the past decade. TMO is a premier growth compounder in the healthcare sector, benefiting from secular tailwinds in drug development, precision medicine, and bioproduction.

Aging Population Stocks

Thermo Fisher Scientific is the world's largest life sciences tools company, providing essential instruments, reagents, and diagnostics that serve aging population healthcare and pharmaceutical R&D needs.

Growth Stocks

Thermo Fisher Scientific has delivered consistent double-digit earnings growth through organic expansion and strategic acquisitions, making it one of the premier growth compounders in the healthcare sector with a long runway for continued expansion.

Healthcare Stocks

Thermo Fisher Scientific is the world's largest life sciences tools and diagnostics company, providing essential instruments, reagents, and services to hospitals, laboratories, pharmaceutical companies, and research institutions globally.

Key Financials TMO

Price $504.82
Change (1D) -0.98%
Change (30D) -12.88%
Change (60D) -10.99%
Change (90D) -7.19%
Change (180D) +25.54%
Change (1Y) -6.17%
Change (5Y) +3.17%
P/E Ratio 46.40
EPS (TTM) $10.88
52-Week Range $385.46 โ€” $643.99
50-Day MA $584.45
Volume 3.19M

Data updated Feb 15 ยท Source: Twelve Data

4.4 2 reviews

AI Reviews

๐Ÿค–
4.2 /5

Thermo Fisher Scientific is the world's largest life sciences tools and diagnostics company, serving pharmaceutical, biotech, academic, and clinical customers. Its dominant market position, diversified revenue streams, and essential role in drug development and healthcare diagnostics create a formidable competitive moat.

The stock is trading well below its 52-week high at $504.82, roughly 22% off its peak, and sits below its 50-day moving average of $584.45, signaling near-term technical weakness. The P/E ratio of 46.4x is elevated, reflecting premium pricing for a quality compounder but leaving limited margin of safety. EPS of $10.88 TTM suggests some post-pandemic normalization in earnings after the COVID testing tailwind faded.

Bull case: TMO's acquisition-driven growth model, recurring revenue from consumables and services, and exposure to secular trends like precision medicine and aging demographics support long-term compounding. Bear case: Rich valuation, slowing organic growth in the current macro environment, and potential tariff impacts on global supply chains pose headwinds. The 180-day gain of 25.5% shows underlying resilience despite recent pullback. A strong long-term hold for patient investors, though current entry points demand careful consideration.

Category Ratings

Aging Population Stocks
4.3
Growth Stocks
3.8
Healthcare Stocks
4.5
Feb 15, 2026
AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more
๐Ÿค–
4.5 /5
Thermo Fisher Scientific stands as the premier infrastructure play in the life sciences industry, offering an unrivaled breadth of instruments, consumables, and services. The investment thesis rests on its sticky recurring revenue model and a proven history of value-creating M&A. Currently trading at $527.17, the stock has pulled back significantly from its 52-week high of $644 and sits below its 50-day moving average, reflecting broader concerns about biotech funding constraints and post-pandemic normalization. With a P/E ratio of 30.4, TMO retains a premium valuation that demands consistent execution. While near-term headwinds in China and reduced customer spending may dampen immediate growth, Thermo Fisher's dominant market position makes this dip a compelling consideration for patient investors seeking high-quality exposure to healthcare innovation.

Category Ratings

Growth Stocks
4.2
Healthcare Stocks
4.7
Feb 12, 2026
AI-Generated Review Generated via Google API. This is an automated evaluation, not a consumer review. Learn more